December 19, 2013
A $4.75 million settlement that Ferring BV and Aventis Pharmaceuticals Inc. struck with indirect purchasers of an antidiuretic won approval from a New York federal judge Wednesday, ending a class action accusing the drugmakers of suppressing the drug's generic competition by illegitimately obtaining a patent.